Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
Bristol-Myers Squibb should soon unveil data showing whether Opdivo’s liver cancer use could be broadened from second to first line, while Amicus investors look for a…
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
Licensing deal activity holds up in first half of 2018 as biopharma continues to stay away from takeovers.
Cardiovascular safety is great news, but the main problem with the Eisai drug is that it simply doesn’t work as monotherapy.
Featuring at the European Society of Cardiology meeting, which kicks off this weekend in Munich, are results with tafamidis, Xarelto and fish oil supplements.
The amyloid hypothesis of Alzheimer's has taken another battering – and some companies are finally taking a new approach.
Data on Alzheimer's disease project spoiled by patient exclusions.